Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 3
1949 1
1950 4
1951 9
1952 26
1953 14
1954 6
1955 6
1956 7
1957 16
1958 10
1959 12
1960 5
1961 10
1962 18
1963 29
1964 15
1965 21
1966 17
1967 11
1968 12
1969 8
1970 6
1971 14
1972 22
1973 19
1974 23
1975 13
1976 24
1977 20
1978 32
1979 51
1980 59
1981 72
1982 108
1983 108
1984 133
1985 149
1986 157
1987 202
1988 197
1989 203
1990 249
1991 261
1992 289
1993 358
1994 451
1995 508
1996 607
1997 706
1998 809
1999 1037
2000 1247
2001 1381
2002 1732
2003 2010
2004 2401
2005 2807
2006 3287
2007 3617
2008 4184
2009 4641
2010 5313
2011 5969
2012 6828
2013 7548
2014 8332
2015 9022
2016 9400
2017 9780
2018 10514
2019 12221
2020 14078
2021 15316
2022 16061
2023 16082
2024 19041
2025 21100
2026 6048
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200,730 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical Characterization of DPI-4452: A (68)Ga/(177)Lu Theranostic Ligand for Carbonic Anhydrase IX.
Massière F, Wiedemann N, Borrego I, Hoehne A, Osterkamp F, Paschke M, Zboralski D, Schumann A, Bredenbeck A, Brichory F, Attinger A. Massière F, et al. J Nucl Med. 2024 May 1;65(5):761-767. doi: 10.2967/jnumed.123.266309. J Nucl Med. 2024. PMID: 38514083 Free PMC article.
In HT-29 and SK-RC-52 xenograft mouse models, both [(68)Ga]Ga-DPI-4452 and [(177)Lu]Lu-DPI-4452 showed tumor-selective uptake; in addition, [(177)Lu]Lu-DPI-4452 significantly reduced tumor growth. ...Conclusion: DPI-4452 selectively targets CAIX. [(68) …
In HT-29 and SK-RC-52 xenograft mouse models, both [(68)Ga]Ga-DPI-4452 and [(177)Lu]Lu-DPI-4452 showed tumor-selective uptake; …
Preclinical Evaluation of (68)Ga- and (177)Lu-Labeled Integrin alpha(v)beta(6)-Targeting Radiotheranostic Peptides.
Ganguly T, Bauer N, Davis RA, Foster CC, Harris RE, Hausner SH, Roncali E, Tang SY, Sutcliffe JL. Ganguly T, et al. J Nucl Med. 2023 Apr;64(4):639-644. doi: 10.2967/jnumed.122.264749. Epub 2022 Oct 7. J Nucl Med. 2023. PMID: 36207137 Free PMC article.
The peptides were radiolabeled with (68)Ga and (177)Lu. In vitro cell binding, internalization, and efflux of (68)Ga-1 and (177)Lu-2 were evaluated in alpha(v)beta(6)-positive BxPC-3 human pancreatic cancer cells. ...Biodistribution was performed for (68)Ga-1 …
The peptides were radiolabeled with (68)Ga and (177)Lu. In vitro cell binding, internalization, and efflux of (68)Ga-1 and (177)Lu …
Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent (177)Lu-Labeled Radiohapten.
Vaughn BA, Lee SG, Vargas DB, Seo S, Rinne SS, Xu H, Guo HF, Le Roux AB, Gajecki L, Krebs S, Yang G, Ouerfelli O, Zanzonico PB, Fung EK, St Jean S, Carrasco SE, Jungbluth A, Cheung NKV, Larson SM, Veach DR, Cheal SM. Vaughn BA, et al. J Nucl Med. 2024 Oct 1;65(10):1611-1618. doi: 10.2967/jnumed.124.267685. J Nucl Med. 2024. PMID: 39168519 Free PMC article.
Pretargeting [(177)Lu]Lu-Gemini to GPA33-expressing SW1222 human colorectal xenografts was highly effective, leading to absorbed doses of [(177)Lu]Lu-Gemini for blood, tumor, liver, spleen, and kidneys of 3.99, 455, 6.93, 5.36, and 14.0 cGy/MBq, …
Pretargeting [(177)Lu]Lu-Gemini to GPA33-expressing SW1222 human colorectal xenografts was highly effective, leading to …
Cure of Disseminated Human Lymphoma with [(177)Lu]Lu-Ofatumumab in a Preclinical Model.
Shim K, Longtine MS, Abou DS, Hoegger MJ, Laforest RS, Thorek DLJ, Wahl RL. Shim K, et al. J Nucl Med. 2023 Apr;64(4):542-548. doi: 10.2967/jnumed.122.264816. Epub 2022 Nov 10. J Nucl Med. 2023. PMID: 36357179 Free PMC article.
Although immunotherapies that target CD20 on most non-Hodgkin lymphoma (NHL) cells have improved patient outcomes, current therapies are inadequate because many cases are, or become, refractory or undergo relapse. Here, we labelled the third-generation human anti-CD20 anti …
Although immunotherapies that target CD20 on most non-Hodgkin lymphoma (NHL) cells have improved patient outcomes, current therapies are ina …
First-in-Human Serum Stability Studies of [(177)Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy.
Felber V, Holzleitner N, Joksch M, Suhrbier T, von Amsberg G, Schwarzenböck S, Kurth J, Heuschkel M, Günther T, Krause BJ. Felber V, et al. J Nucl Med. 2025 Jun 2;66(6):896-899. doi: 10.2967/jnumed.124.269132. J Nucl Med. 2025. PMID: 40306971 Free PMC article.
This study aimed to analyze the serum stability of [(177)Lu]Lu-AMTG in human subjects due to the compound's high stability observed preclinically and to elucidate its therapeutic potential. ...Results: At 1 h after injection, the mean SD in vivo serum stabi …
This study aimed to analyze the serum stability of [(177)Lu]Lu-AMTG in human subjects due to the compound's high stabil …
Protection of Kidney Function with Human Antioxidation Protein alpha(1)-Microglobulin in a Mouse (177)Lu-DOTATATE Radiation Therapy Model.
Kristiansson A, Ahlstedt J, Holmqvist B, Brinte A, Tran TA, Forssell-Aronsson E, Strand SE, Gram M, Åkerström B. Kristiansson A, et al. Antioxid Redox Signal. 2019 May 10;30(14):1746-1759. doi: 10.1089/ars.2018.7517. Epub 2018 Aug 14. Antioxid Redox Signal. 2019. PMID: 29943622 Free PMC article. Review.
RESULTS: We describe nephroprotective effects of human recombinant A1M on the short- and long-term renal damage observed following lutetium 177 ((177)Lu)-DOTATATE (150 MBq) exposure in BALB/c mice. ...After 6, 12, and 24 weeks (long term), (177)Lu-DOTATATE in …
RESULTS: We describe nephroprotective effects of human recombinant A1M on the short- and long-term renal damage observed following lu …
Comparison of novel PSMA-targeting [(177)Lu]Lu-P17-087 with its albumin binding derivative [(177)Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study.
Li L, Wang J, Wang G, Wang R, Jin W, Zang J, Sui H, Jia C, Jiang Y, Hong H, Zhu L, Alexoff D, Ploessl K, Kung HF, Zhu Z. Li L, et al. Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2794-2805. doi: 10.1007/s00259-024-06721-x. Epub 2024 Apr 25. Eur J Nucl Med Mol Imaging. 2024. PMID: 38658392
After administration of [(177)Lu]Lu-P17-087 and [(177)Lu]Lu-P17-088, 3/5 and 3/4 patients showed reducing PSA values, respectively. CONCLUSION: [(177)Lu]Lu-P17-088 and [(177)Lu]Lu-P17-087 displayed different pharmacokinetics …
After administration of [(177)Lu]Lu-P17-087 and [(177)Lu]Lu-P17-088, 3/5 and 3/4 patients showed reducing PSA va …
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, de Ridder C, Stuurman D, Konijnenberg MW, van Weerden WM, de Jong M, Nonnekens J. Ruigrok EAM, et al. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1339-1350. doi: 10.1007/s00259-020-05057-6. Epub 2020 Oct 23. Eur J Nucl Med Mol Imaging. 2021. PMID: 33094433 Free PMC article.
Autoradiography assays on cryosections of human salivary and renal tissues revealed [(177)Lu]Lu-PSMA-617 to have the lowest binding to these healthy organs compared with [(177)Lu]Lu-PSMA-I&T. ...CONCLUSION: [(177)Lu]Lu-PSMA-617 …
Autoradiography assays on cryosections of human salivary and renal tissues revealed [(177)Lu]Lu-PSMA-617 to have the lo …
Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives (68)Ga/(177)Lu-LNC1011 as Prostate Cancer Theranostics.
Yang H, Wang J, Wen X, Guo H, Jakobsson V, Zhao T, Zeng F, Shen H, Zhang H, Liu X, Qin Y, Li X, Xiong H, Zhou Z, Zhang J, Chen X. Yang H, et al. J Nucl Med. 2025 May 1;66(5):739-747. doi: 10.2967/jnumed.124.268959. J Nucl Med. 2025. PMID: 40113222
Biodistribution studies confirmed the significantly higher tumor uptake of [(177)Lu]Lu-LNC1011 (127.36 16.95 %ID/g) over [(177)Lu]Lu-PSMA-617 (17.44 6.29 %ID/g) at 4 h after injection, and no decrease was measured for the [(177)Lu]Lu- …
Biodistribution studies confirmed the significantly higher tumor uptake of [(177)Lu]Lu-LNC1011 (127.36 16.95 %ID/g) over [(1 …
Human Absorbed Dose Evaluation of [177Lu]Lu-IBA as a Bone Palliative Candidate.
Ranjbar H, Pourhabib Z. Ranjbar H, et al. Nuklearmedizin. 2021 Oct;60(5):375-380. doi: 10.1055/a-1486-3683. Epub 2021 Jun 8. Nuklearmedizin. 2021. PMID: 34102691 English.
The aim of this study was to evaluate of [(177)Lu]Lu-IBA efficacy as a new compound.The [(177)Lu]Lu-IBA was prepared by radiolabeling of IBA ligand to (177)LuCl3 that was obtained by thermal neutron irradiation of enriched Lu2O3 sample. ...With calcula …
The aim of this study was to evaluate of [(177)Lu]Lu-IBA efficacy as a new compound.The [(177)Lu]Lu-IBA was prep …
200,730 results
You have reached the last available page of results. Please see the User Guide for more information.